A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.41 which represents a slight increase of $0.07 or 5.22% from the prior close of $1.34. The stock opened at $1.37 and touched ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

On Friday, Chardan Capital Markets adjusted its rating on shares of Editas Medicine (NASDAQ:EDIT), shifting from Buy to Neutral, adding pressure to a stock that has already ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.22 which represents a decrease of $-0.02 or -1.61% from the prior close of $1.24. The stock opened at $1.26 and touched a low of $1 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...